# Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Source: https://onco.cc/trials/nct06072612/  
OnCo record `nct06072612` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cyclophosphamide and Retifanlimab in advanced solid tumours, run by BriaCell Therapeutics Corporation, now recruiting.

## Summary

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. is a phase 3 interventional study registered as NCT06072612 by BriaCell Therapeutics Corporation, with 404 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-12. Interventions recorded: SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab and Treatment of Physician's Choice.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06072612
- Phase: 3
- Setting: Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Sponsor: BriaCell Therapeutics Corporation
- Enrolled: 404

## Sources

- ClinicalTrials.gov NCT06072612: https://clinicaltrials.gov/study/NCT06072612

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Retifanlimab](https://onco.cc/drugs/retifanlimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06072612.json